Skip to main content
OpenTrials
Completed

NCT Number: NCT00237913

Schizophrenia Trial of Aripiprazole

Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Local Institution, Vienna, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of schizophrenia
  • Schizophrenia symptoms not optimally controlled or antipsychotic medication not well tolerated

Exclusion criteria

  • Diagnosis of schizoaffective disorder
  • Patients treatment-resistant to antipsychotics

Treatment and study plan

Aripiprazole

Drug

Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.

Other names: Abilify

Olanzapine or Quetiapine or Risperidone

Drug

Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.

Primary outcomes

  1. Score on the Investigator Assessment Questionnaire at week 26

Secondary outcomes

  1. Clinical Global Impression scale and patient preference of medication at endpoint

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Industry

Collaborators

  • Otsuka America Pharmaceutical

Registry information

Official study title

A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)

Important dates

Study start
2004
Primary completion
2005
Study completion
2005
First posted
Oct 13, 2005
Registry last updated
Nov 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.